PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin
Abstract
Chemoresistance contributes to relapse in high-risk neuroblastoma. Cancer cells acquire resistance through multiple mechanisms, including drug efflux pumps. In neuroblastoma, multidrug resistance-associated protein-1 (MRP1/ABCC1) efflux pump expression correlates with worse outcomes. These pumps are regulated by PIM kinases, a family of serine–threonine kinases, overexpressed in neuroblastoma. We hypothesized PIM kinase inhibition would sensitize neuroblastoma cells by modulating MRP1.
Keywords
NeuroblastomaChemoresistancePim Kinase InhibitionMrp1 Efflux PumpDoxorubicinPediatric OncologyTargeted TherapyHashtags
#Neuroblastoma#PediatricOncology#Chemoresistance#TargetedTherapyThis article is published on an external journal. Click below to read the full text.
Read full article ↗How to cite: GlobalCastMD. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin. GlobalCastMD Medical Library. 2024-03-14. https://origin-library.globalcastmd.com/article/8151
Comments (0)